Bristol Myers Squibb stock trades steadily as oncology pipeline and Revlimid erosion shape outlook

Bristol Myers Squibb stock represents exposure to one of the largest global biopharmaceutical groups, with the issuer Bristol Myers Squibb Co. (ISIN US0897961004) listed on the New York Stock Exchange and known for blockbuster oncology and cardiovascular drugs. The companys latest reported annual figures show total revenue of around $45.0 billion in fiscal 2024, underlining the scale of its portfolio and the importance of balancing patent erosion with new launches.

Revenue near $45 billion with portfolio shift

According to the companys investor information for fiscal 2024, Bristol Myers Squibb generated approximately $45.0 billion in total revenue, compared with about $46.4 billion in fiscal 2023, reflecting a modest decline of around 3% as legacy products like Revlimid face increasing generic competition. Within that total, revenues from the hematology and oncology franchise remained above $20 billion in 2024, but declined versus the prior year as Revlimid sales fell from an estimated level of more than $8 billion in 2023 to closer to $6 billion in 2024 due to generic entry and pricing pressure.

Cardiovascular and thrombosis therapies continued to contribute a large share of turnover. The oral anticoagulant Eliquis, co-developed with a major European peer, delivered more than $11 billion in global net sales in fiscal 2024, up from roughly $10.5 billion in 2023, supported by ongoing adoption in stroke prevention and treatment of venous thromboembolism. This mid-single-digit percentage growth in Eliquis helped offset weakness in Revlimid and other maturing brands, illustrating how Bristol Myers Squibb is relying on its newer assets to stabilize top-line performance.

Opdivo and newer launches support growth

In oncology, immune checkpoint inhibitor Opdivo remained one of Bristol Myers Squibbs most important growth drivers. Company data for fiscal 2024 indicate that Opdivo net sales reached about $9.0 billion, compared with roughly $8.2 billion in 2023, representing an increase of around 9.8% year on year. This growth reflects expanded indications across lung, melanoma, renal, and other tumor types, as well as combinations with other immunotherapies and targeted drugs that enhance treatment outcomes and drive higher usage.

The firm is also investing heavily in next-generation therapies beyond its established blockbuster portfolio. A key example is cardiomyopathy treatment Camzyos, a targeted therapy for hypertrophic cardiomyopathy that Bristol Myers Squibb acquired via its purchase of MyoKardia. In fiscal 2024, Camzyos net sales reached several hundred million dollars, significantly above the roughly $100 million range reported in 2023, highlighting a rapid ramp-up from launch and the potential for this drug to become a meaningful contributor to cardiovascular revenue over the medium term.

Beyond these flagship products, Bristol Myers Squibb has advanced multiple cell therapy candidates and other oncology assets through late-stage development. The companys pipeline metrics show more than 20 late-stage programs across oncology, hematology, immunology, and cardiovascular disease as of fiscal 2024, giving it a broad base of potential future launches that may help offset further declines in Revlimid and other aging brands.

Profitability and cash generation remain key

Profitability remains an important consideration for Bristol Myers Squibb stock. For fiscal 2024, the company posted GAAP net income of around $8.0 billion, compared with approximately $7.3 billion in 2023, implying growth of around 9.6% despite modest revenue compression. This improvement was driven by cost discipline, portfolio mix shifts toward higher-margin products, and lower integration charges following prior acquisitions. On a per-share basis, GAAP earnings per share for 2024 were in the region of $4.50, up from about $4.10 in 2023.

Adjusted figures, which strip out one-time items and amortization related to past deals, were higher and often used by market participants to assess the underlying profitability of Bristol Myers Squibb. The company reported non-GAAP EPS in fiscal 2024 of roughly $7.50, compared with around $7.20 in 2023, reflecting a mid-single-digit percentage increase even as revenues edged slightly lower. This demonstrates how management is trying to protect margins through streamlining operations and focusing resources on core therapeutic areas.

Cash generation supports ongoing investment in R&D and shareholder returns. Operating cash flow for fiscal 2024 was reported at more than $12 billion, in line with or slightly above the level seen in 2023, helping Bristol Myers Squibb to fund its high research and development budget, which stood at roughly $9 billion in 2024. The group also maintained a sizeable dividend; its annual dividend per share amounted to around $2.40 in 2024, up from about $2.28 in 2023, indicating a modest year-on-year increase and signaling managements confidence in future cash flows.

Revlimid erosion versus pipeline potential

For investors following Bristol Myers Squibb stock, the balance between Revlimid erosion and pipeline potential is central. Revlimid, a multiple myeloma therapy originally part of the Celgene acquisition, has been a major cash generator but is now exposed to generic competition. Company figures show that Revlimid revenue dropped from more than $8 billion in 2023 to roughly $6 billion in 2024, equating to a decline of about 25% year on year. This contraction illustrates the scale of patent-expiry headwinds facing the company as it moves through the so-called LOE, or loss-of-exclusivity, period for several legacy products.

To counteract this, Bristol Myers Squibb is pushing forward several newer drugs, particularly in oncology and immunology. Among the notable examples are cell therapies like Abecma and Breyanzi which are used to treat multiple myeloma and certain lymphomas. Combined sales for these cell therapies reached more than $1 billion in fiscal 2024, up strongly from the hundreds-of-millions range in 2023, underlining their momentum as they move further into clinical practice.

Management guidance for the mid-term period points to a shift in revenue composition, with a growing share expected from these newer assets and from cardiovascular therapies like Camzyos and Eliquis. The company has indicated that the so-called next-wave products could collectively deliver several billion dollars in incremental revenue by the late 2020s, helping to rebase the top line once the Revlimid headwinds are absorbed.

Valuation, market capitalization, and index role

Bristol Myers Squibb is one of the larger constituents of major US equity indices, including the S&P 500. As of early 2026, the companys market capitalization was in the region of $90 billion, reflecting the aggregated value that the market assigns to its current portfolio, pipeline, and cash flows. This capitalization figure has eased from levels above $100 billion seen during earlier periods when Revlimid contribution was higher and valuation multiples were somewhat more generous.

The stock trades actively on the New York Stock Exchange under the ticker BMY, with daily average trading volumes running into several million shares. The share price has tended to oscillate within a range shaped by pipeline news, regulatory decisions, and evolving perceptions of patent-expiry risk. Over the 52-week period to early 2026, Bristol Myers Squibb stock moved between approximately $45 at the lower end of the range and around $60 at the upper end, reflecting differing episodes of optimism and caution as investors weighed disappointing data from some trials against strong commercialization of approved assets.

From a performance perspective, the shares have not matched the rally seen in some pure-play high-growth biotechnology names, but they have offered defensive qualities linked to the companys established revenue base and dividend policy. Total shareholder return over the three-year period leading into 2026 was moderate, with price performance roughly flat to slightly negative and dividends providing the bulk of realized return for long-term holders.

Dividend policy and capital allocation

Dividend policy is an important part of Bristol Myers Squibbs appeal to income-focused investors. The firm has steadily increased its dividend over time. For fiscal 2024, the annualized dividend per share was around $2.40, as noted earlier, compared with approximately $2.28 in fiscal 2023 and closer to $2.16 in 2022. These changes indicate low- to mid-single-digit annual growth in the payout, in line with managements stated aim of maintaining a sustainable and gradually rising dividend aligned with earnings and cash flows.

Alongside dividends, Bristol Myers Squibb engages in share repurchases when management views the stock valuation as attractive relative to its intrinsic assessment. In fiscal 2024, the company executed buybacks in the low single-digit billions of dollars, reducing the share count and providing incremental support to per-share earnings. The company also continues to allocate substantial capital to research and development spending, with the roughly $9 billion R&D budget for 2024 representing around 20% of total revenue, a level that underscores its commitment to innovation in oncology, hematology, immunology, and cardiovascular disease.

Debt management is another capital-allocation pillar. Bristol Myers Squibb carried long-term debt in the tens of billions of dollars following the acquisitions of Celgene and MyoKardia, but has gradually reduced this burden through repayments. By fiscal 2024, net debt had declined versus earlier post-acquisition peaks, and the companys leverage ratios were more comfortable, with net debt to adjusted EBITDA moving toward a mid-two-times range, giving it flexibility to pursue further targeted deals or respond to competitive developments.

Clinical and regulatory milestones

The value case for Bristol Myers Squibb stock depends heavily on clinical and regulatory milestones. Recent years have seen important approvals and label expansions for key therapies. For Opdivo, regulators granted new indications in several tumor types between 2022 and 2024, broadening the addressable patient population and supporting the near 10% revenue growth recorded in fiscal 2024. Eliquis continued to benefit from guideline support and real-world data in atrial fibrillation and venous thromboembolism, which reinforced its status as a leading factor Xa inhibitor.

Cell therapy approvals have been particularly noteworthy. Abecma became one of the first BCMA-directed CAR-T cell therapies for multiple myeloma, and Breyanzi targets CD19 in certain lymphoma indications. Each therapy carries complex manufacturing and logistical requirements but offers potentially transformative benefits for heavily pre-treated patients. Regulatory filings and approvals in new geographies or earlier lines of therapy could further expand their commercial footprint over the coming years.

At the same time, Bristol Myers Squibb has experienced setbacks in some development programs, reminding investors of the inherent risks in late-stage drug development. Certain immunology and oncology candidates have seen mixed trial results, leading to occasional discontinuations or delays. Such outcomes are part of the normal course of biopharmaceutical R&D, but they can influence sentiment when they involve high-profile assets that were previously expected to contribute significantly to future revenue.

Therapeutic focus and competitive landscape

Bristol Myers Squibb maintains a clear focus on selected therapeutic areas where it believes it can sustain a competitive edge. Oncology and hematology remain central, with flagship drugs like Opdivo, Revlimid, and its cell therapies forming the backbone of this portfolio. Immunology and cardiovascular disease are also strategically important, with therapies such as Eliquis and Camzyos demonstrating that Bristol Myers Squibb is not solely an oncology company but has a broader presence in serious chronic conditions.

The competitive landscape is intense in each of these segments. In oncology, Bristol Myers Squibb faces competition from other large pharmaceutical and biotechnology firms that are advancing their own checkpoint inhibitors, targeted therapies, and cell-based approaches. In cardiovascular disease, Eliquis competes with other direct oral anticoagulants and traditional therapies such as warfarin. The companys ability to maintain market share depends on both clinical outcomes and real-world data as well as pricing strategies and reimbursement agreements.

In cell therapy, manufacturing capacity, safety profile, and long-term durability of response are crucial competitive factors. Bristol Myers Squibb is continuing to refine its production processes and supply chains to support broader use of Abecma and Breyanzi, as these therapies move beyond the initial specialist centers and into a more widespread treatment environment.

R&D investment and pipeline breadth

Research and development activity is central to Bristol Myers Squibbs long-term value proposition. The approximately $9 billion R&D budget in 2024 represented a sizable commitment to advancing new medicines across its key areas and exploring novel modalities such as cell therapy, protein homeostasis modulators, and targeted therapies. The companys pipeline includes dozens of early- and mid-stage candidates, with more than 20 in late-stage development as noted earlier. These late-stage assets are likely to have the most immediate impact on revenues and earnings if they achieve approval.

Painstaking trial design and regulatory dialogue are necessary components of this strategy. Bristol Myers Squibb invests heavily in understanding biomarkers and patient stratification, particularly in oncology, where precision medicine approaches can drive better outcomes and differentiate a drug from competitors. It also collaborates with academic centers and smaller biotechnology firms to access emerging science that may be relevant to future therapies.

For investors, the breadth of the pipeline provides some diversification against the risk that any single candidate fails to meet expectations. However, given the scale of the company, only those assets capable of delivering hundreds of millions or billions of dollars of annual sales will meaningfully move the needle at the level of group revenues and profits.

Regulatory and pricing environment

The regulatory and pricing environment is a critical external factor influencing Bristol Myers Squibb stock. Healthcare systems worldwide are under pressure to manage costs while still providing access to innovator therapies. Discussions around drug pricing, value-based reimbursement, and generic competition are ongoing in the United States and other key markets. Bristol Myers Squibb must navigate these dynamics while protecting its earnings base and funding innovation.

Loss of exclusivity, observed clearly in the case of Revlimid, is one manifestation of this environment. Once generic competitors enter, pricing typically declines and volumes may shift. The companys strategy is therefore to maintain a steady flow of new innovative drugs into the market so that LOE headwinds are balanced by emerging revenue streams from younger products.

In parallel, Bristol Myers Squibb engages with policymakers and payers to demonstrate the clinical and economic value of its therapies, including measures such as reduced hospitalizations or improved survival. Such data can support favorable reimbursement decisions and mitigate pressure on list prices.

Sustainability and ESG considerations

Sustainability and environmental, social, and governance (ESG) considerations are increasingly relevant for large pharmaceutical issuers. Bristol Myers Squibb reports on its ESG performance, including commitments to patient access, workforce diversity, environmental impact, and ethical conduct. While these factors are less directly quantifiable than revenue or earnings metrics, they influence the companys long-term reputation and can affect investor perception, particularly among institutional investors that have ESG mandates.

The company has initiatives aimed at expanding access to medicines in low- and middle-income countries and at limiting its environmental footprint across manufacturing sites, logistics, and office operations. It also has governance structures that seek to align management incentives with long-term shareholder interests and compliance with relevant regulations.

Camzyos and cardiovascular growth

Camzyos, the targeted therapy for hypertrophic cardiomyopathy acquired via the MyoKardia deal, is a good example of how Bristol Myers Squibb is broadening its cardiovascular portfolio. Net sales in fiscal 2024, at several hundred million dollars and significantly above the approximately $100 million level in 2023, suggest that cardiologists are increasingly adopting the drug for certain symptomatic patients. If further data confirm beneficial effects on long-term outcomes and quality of life, Camzyos could continue to gain traction and help to diversify revenue away from older anticoagulant therapies.

Unlike some of Bristol Myers Squibbs legacy products, Camzyos represents a more targeted approach, focusing on specific mechanisms within the heart muscle. This aligns with the broader industry trend toward precision therapies where interventions are designed to address underlying disease pathways rather than just symptoms. The success of Camzyos and similar drugs will be an important indicator of whether Bristol Myers Squibb can remain at the forefront of cardiovascular innovation alongside its strong presence in oncology.

Bristol Myers Squibb product snapshot

Beyond the financial metrics, Bristol Myers Squibb is known in everyday healthcare settings for its medicines that address serious diseases. Key brands such as Opdivo, Eliquis, Revlimid, Abecma, Breyanzi, and Camzyos appear regularly in treatment protocols across oncology and cardiology. Together, these products illustrate how Bristol Myers Squibb participates in both acute and chronic disease management and why its revenue base has historically been stable.

Volume trends for these therapies can vary based on guideline updates, competitive launches, and real-world evidence. For instance, Eliquis volumes have grown steadily as physicians continue to switch from older anticoagulants to direct oral agents, while Revlimid volumes have been pressured by generics. Meanwhile, cell therapies like Abecma and Breyanzi are seeing rising utilization as more treatment centers gain experience with CAR-T technologies.

Bristol Myers Squibb stock and recent trading levels

Bristol Myers Squibb stock trades on the New York Stock Exchange under the ticker BMY. As of early 2026, the shares were quoted near $55, placing them closer to the middle of the recent 52-week range between about $45 and roughly $60. This level reflects investors current assessment of the companys prospects, balancing near-term revenue headwinds from Revlimid against ongoing growth in Opdivo, Eliquis, Camzyos, and cell therapies, as well as the potential of the broader pipeline.

Key oncology brands drive value

In oncology, Bristol Myers Squibb continues to prioritize indications where its therapies can deliver survival benefits and durable responses. Opdivo remains a core asset, with revenue of around $9.0 billion in 2024 as already noted, and Abecma and Breyanzi are gradually adding meaningful revenue streams in hematologic malignancies. The company also has other important drugs such as Yervoy, a CTLA-4 inhibitor often used in combination with Opdivo, whose revenues, while smaller than those of Opdivo, contribute to the overall oncology franchise.

Oncology revenues are sensitive to clinical-trial outcomes. Positive data can support label expansions and drive incremental usage, while negative or inconclusive results may limit growth. Bristol Myers Squibb has historically been active in combining its therapies with others, whether internal assets or external partners, to design regimens that can provide better efficacy or tolerability. Such combination strategies require careful trial design and regulatory coordination but can significantly increase the value of individual drugs.

Cardiovascular and immunology franchises

In cardiovascular disease, Eliquis and Camzyos are the key brands. Eliquis, with more than $11 billion of net sales in 2024, is central to the companys revenue stream and widely used in the prevention of stroke in atrial fibrillation and the treatment of venous thromboembolism. The drugs success relies on both clinical performance and widespread guideline inclusion. The company monitors real-world data to demonstrate low rates of major bleeding and strong efficacy, which are critical selling points compared with older therapies.

Camzyos, as discussed, offers a more targeted approach to hypertrophic cardiomyopathy. Its adoption trajectory will depend heavily on emerging data and practical experience in cardiology centers, as well as payer acceptance for a specialized therapy. If uptake continues to accelerate, Camzyos could reach the billion-dollar revenue mark over the medium term, contributing substantially to Bristol Myers Squibbs cardiovascular franchise.

In immunology, Bristol Myers Squibb has therapies aimed at autoimmune conditions, though this franchise is smaller than its oncology presence. Strategies may include leveraging insights from oncology immune modulation to develop new treatments for autoimmune diseases, potentially broadening the companys revenue base and providing diversification.

Long-term considerations for Bristol Myers Squibb stock

Long-term holders of Bristol Myers Squibb stock generally focus on a set of recurring questions: how effectively the company can replace revenues from aging blockbusters, whether the pipeline can deliver enough high-impact launches, and how management balances shareholder returns with reinvestment in innovation. The revenue decline from Revlimid, falling from more than $8 billion in 2023 to roughly $6 billion in 2024, is a prominent example of the replacement challenge. It shows how rapidly a major product can lose revenue once generic competition arrives.

On the other side of the ledger, drugs such as Opdivo, Eliquis, Camzyos, and the companys cell therapies demonstrate that Bristol Myers Squibb can create new franchises from emerging science. These assets have collectively generated billions of dollars of incremental revenue in recent years. Whether that momentum will be sufficient to fully offset patent-expiry headwinds is a central consideration for valuation and for how investors view the stock relative to peers.

Other long-term factors include regulatory changes, potential industry consolidation, and macroeconomic conditions affecting healthcare budgets. Bristol Myers Squibb has a track record of using large acquisitions to reshape its portfolio, as seen in the Celgene and MyoKardia deals, but future M&A will depend on opportunities and valuation conditions.

Representative product Camzyos

Camzyos stands out as a representative example of Bristol Myers Squibbs newer generation of targeted therapies. Approved for certain patients with symptomatic obstructive hypertrophic cardiomyopathy, it provides a more specific intervention than conventional treatment options. As mentioned earlier, Camzyos net sales climbed from about $100 million in fiscal 2023 to several hundred million dollars in 2024, indicating rapid growth from a relatively small base.

The drugs mechanism involves modulation of cardiac muscle contractility, which can help reduce obstruction and improve symptoms. Its future growth will depend on factors such as further clinical evidence, potential additional indications, and payer decisions. If expanded successfully, Camzyos could contribute meaningfully to the cardiovascular franchise alongside Eliquis, helping Bristol Myers Squibb to diversify beyond its oncology core.

Bristol Myers Squibb stock price and market context

As of early 2026, Bristol Myers Squibb stock is trading around $55 on the New York Stock Exchange, which places the shares in the mid-point of the recent 52-week range between roughly $45 and $60. This price level implies a market capitalization near $90 billion, reflecting investor assessments of the companys earnings power, pipeline prospects, and risk profile relative to other large-cap pharmaceutical peers.

The shares have experienced periods of both optimism and caution, depending on clinical-trial headlines and regulatory news. When data confirm the value of key pipeline assets or show stronger-than-expected performance for existing products, sentiment tends to improve. Conversely, weaker data or heightened concerns about drug pricing and patent expiries can weigh on the stock. In this context, Bristol Myers Squibbs combination of a substantial dividend, strong cash generation, and a large pipeline may appeal to investors seeking exposure to innovative biopharmaceuticals while still valuing income and defensive characteristics.